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ABSTRACT 
 
JUSTIN R. VALENTINE: Impact of Periodontal Intervention on Local 
Inflammation, Periodontal Disease and HIV Outcomes 
(Under the direction of Jennifer Webster-Cyriaque, Janet Southerland, and Thiago Morelli) 
 
Forty-six percent of the United States population is infected with periodontitis, and of 
these, 37.1 and 8.9% suffer from severe and mild to moderate forms of the disease, respectively. 
1.2 million persons in the US are also diagnosed with HIV. Increasing evidence suggests that the 
chronic periodontal infection is implicated in the generation of a systemic inflammatory 
response, which represents a potential risk factor for worsening various systemic conditions, 
including HIV. It has been reported in the literature that gut microbial translocation can lead to 
immune activation of HIV. There are few if any studies investigating the potential impact of 
microbial translocation of the oral cavity on HIV and, importantly, the impact that the resolution 
of oral inflammation has on HIV immune status.  
The purpose of this study was to identify periodontal disease status and disease resolution 
following periodontal intervention, and assess the therapeutic response of local inflammation and 
HIV outcomes, as measured by pro-inflammatory cytokine IL-6, CD4 cell count and HIV viral 
load in a cohort of HIV positive patients.
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CHAPTER 1: THE EVIDENCE OF BACTERIA, INFLAMMATION AND VIRUSES IN 
PERIODONTAL DISEASE PATHOGENESIS 
 
INTRODUCTION 
 
Polymicrobial infections are central to the pathogenesis of many diseases. These 
infections incite the host immune system and the potential for pathogen-pathogen interactions in 
this setting may worsen disease. Oral infections of the periodontium are characterized by 
multiple bacterial agents, and more recently, viral infections as well. Traditionally, periodontal 
disease has been characterized as an inflammatory disease caused by bacteria found in dental 
plaque and the host immune response. 
 This review serves to discuss periodontal disease and its associated host responses, the 
potential molecular mechanisms that arise during viral and bacterial co-infections, the role of 
viruses in periodontal disease and periodontal disease in the setting of systemic viral infection 
and immune suppression. 
Section 1.1 Periodontal Disease 
Periodontal disease is an inflammatory disease that may lead to the loss of supporting 
bone, cementum and periodontal ligament, and could ultimately lead to exfoliation of the teeth. 
The disease is broadly categorized into two forms: gingivitis, which affects the gingival tissues 
surrounding the teeth; and periodontitis, which affects the gingival tissues, bone, cementum and 
periodontal ligament surrounding the teeth. Periodontitis is always preceded by gingivitis; 
however, not all gingivitis lesions will progress to periodontitis. Over the course of time, various 
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concepts of the etiology of periodontal disease have and continue to evolve. What follows is a 
brief historical overview of the etiology of periodontal disease. 
  Periodontal disease has been documented since antiquity. Earliest known documentations 
are from Ancient Egyptian Hieratic writings. Dating back to approximately 3700 BC, Ebers 
papyrus from Egyptian documents detailed some of the early practices of medicine. In these 
documents, there are references to periodontal disease, described as “throbbing blisters” in teeth, 
likely periodontal abscesses.1 It was also documented that various surgical treatments led to 
“strengthening of the flesh” or gums. Other ancient cultures would also record similar 
observations of periodontal disease, including India, China and Greece. During this time period, 
periodontal disease, as well as most diseases, was thought to originate from divine intervention 
and retribution of sinful acts. Thus, treatment was often associated with religion, through various 
rituals and prayers.1 
During the Arabic period of medical history (622AD-1492), newer concepts and 
treatments in medicine evolved. In the 18th century, dentistry began separating from medicine 
and developed into its own profession and concepts of periodontal disease started to evolve. 
Such theories were published in The Surgeon Dentist by Pierre Fauchard, 1728. Fauchard is 
regarded as the father of modern dentistry and described periodontal disease as a local 
phenomenon of the oral cavity characterized by inflamed, edematous gums often with purulence, 
and associated these findings with poor oral hygiene. What was unknown at the time was what 
entity caused the disease. Fauchard was correct in his assessment of the link between oral debris 
and periodontal disease. But it would not be until the discovery of bacteria by Van Leuwenhoek 
in 17th century that the composition of this debris would be characterized and set the stage for the 
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role of bacteria in periodontal disease. William Younger was one of the first dentists to suggest 
that periodontal disease was of bacterial etiology in his work Pyorrhea Alveolaris, 1905.  
Currently, periodontal disease is believed to involve primarily two factors: bacteria and 
the host response, which are influenced by genetics and modified by various risk factors, such as 
smoking and diabetes.2 Although studies have shown strong associations between bacteria and 
periodontal disease, bacterial alone do not fully explain the expression of the disease. As 
Offenbacher stated, “bacteria are necessary but not sufficient” for periodontal disease.2 The 
objectives of this review are to summarize the evidence of bacteria as a causative agent for 
periodontal disease, the roles of inflammation and viruses in periodontal disease and the 
association between HIV and periodontal disease.   
Section 1.2 Bacterial etiology of Periodontal Disease  
The evidence for a bacterial etiology in periodontal disease is well described in the 
periodontal classical literature. One of the most classic studies showing a clinical relationship 
between bacteria and gingivitis was performed by Loe, et al.3 In this study, twelve subjects with 
good oral hygiene abstained from oral hygiene practices until the development of clinical 
gingivitis. Microbial plaque samples were taken and analyzed with light microscopy from the 
start of the study until the expression of gingivitis, at which time oral hygiene practices were 
reinstituted. All subjects accumulated large amounts of plaque and developed gingivitis. 
Microbial changes were characterized by a change from predominately coccal forms of bacteria 
at the start of the experiment, to filamentous and spirochetal forms during the later part of the 
experiment, when gingivitis was induced. Upon reinstitution of oral hygiene practices, gingival 
health was reestablished in all subjects, and in the majority of subjects, the microbiota returned 
to predominately cocci and short rods, while a minority (17%) of subjects still presented with 
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filamentous bacteria. This classic study demonstrates that in healthy subjects, the occurrence of 
gingivitis was comcominant with the occurrence of increased amounts of microbial plaque and 
changes in the microbial composition of the plaque. Furthermore, removal of the microbial 
plaque led to resolution of the disease, with concomitant return to cocci and short rod forms in 
the majority of subjects.  
Listgarten investigated the structural changes in the microbiota associated with teeth in 
subjects who were periodontally healthy and those with varying severities of periodontal disease, 
including periodontitis, periodontosis and post-periodontotisis, the later two entities representing 
what is currently named aggressive periodontitis.4 The difference between periodontosis and 
post-periodontotis is separated by age, where the former was in subjects ≤21 years of age and the 
later for subjects ≥22 years of age. It was observed that the morphological features of the 
microbiota were significantly different amongst the groups.  
Healthy subjects had bacterial cells predominately coccoid shaped, gram-positive 
organisms. Filamentous and gram-negative organisms were low in number compared to other 
subject groups. Gingivitis samples consisted of densely packed microbial cells associated with 
the tooth surface coronal to the epithelial attachment. The bacterial cells were coccoid and 
filamentous, some flagellated with both gram-positive and gram-negative patterns observed. The 
filamentous bacteria were more numerous and a distinctive “corn-cob” bacterial formation patter 
was observed in some areas. Periodontitis samples consisted of predominantly filamentous 
forms, along with the cell types and patterns identified in gingivitis samples. There were a 
substantially increased number of flagellated bacteria and the deeper pocket layers demonstrated 
“test-tube brush” configurations. Periodontosis samples contained gram-negative coccoid and 
filamentous bacteria and lacked grossly noticeable surface deposits while post-periodontosis 
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samples consisted of flora similar to gingivitis and periodontitis supragingivally, and 
periodontitis in the apical portions.  
From Listgarten’s study, one can appreciate how the complexity of microorganisms 
increases with advancing disease severity. As the periodontal pocket increases in depth, it creates 
an environment conducive to the proliferation of more pathogenic microorganisms. As an 
example, many periodontal pathogens are obligate anerobic organisms. As the depth of the 
pathological pocket and quantity of bacteria increases, the oxygen content of the pocket 
decreases. This can often be observed clinically as cyanosis of the gingival tissues in areas of 
severe gingival inflammation. Furthermore, gingival crevicular fluid, cellular debris, proteins, 
and hemorrhage increase, all of which serve as a nutrient source for bacteria. The biofilm 
formation of the microbiota, as observed by the increase in structural complexity between 
bacteria, allows for communication, sharing of nutrient resources and evasion of host immune 
response and systemic antibiotic effects.  
A study of subgingival microflora and periodontal disease, Slots recruited subjects who 
had gingivitis, advanced adult periodontitis or juvenile periodontitis, while healthy subjects 
served as controls. Subgingival microbial plaque was sampled from the periodontal pocket using 
sterile currettes and bacteria analyzed using anaerobic jar culturing.  It was observed that the 
microbiota differed between subject groups. In healthy individuals, gram-positive bacteria 
dominated the sample, representing 85% of cultivable organisms, primarily Streptococcus and 
Actinomyces species. Gingivitis, adult and juvenile periodontitis had higher amounts of gram 
negative organisms, including  F. nucleatum, B. melaninogenicus, and Bacteroides species. 5  
Socransky identified and grouped oral bacteria into specific complexes based on cluster 
analyses.6 Using 185 subjects, sub-gingival bacterial plaque samples were collected from 
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patients with periodontitis (n=160) and without (n=25). From a total of 13,000 plaque samples, 
checkerboard DNA-DNA hybridization was performed for 40 bacterial taxa. Statistical 
clustering analyses revealed 5 major sub-gingival bacterial complexes: red, orange, green, 
yellow, and purple.  
The red and orange complexes have been associated with periodontitis, while the green 
complex has been associated with health. For example, Socransky showed that species of the red 
and orange complex had a significantly positive association with deep probing depths. Pocket 
depths were their shallowest when red complex bacteria were absent and deepest when in the 
presence of all red complex bacteria. Other studies have identified red complex organisms in 
association with periodontitis.7,8 More recent investigations have further corroborated these 
results.9–15 Virulence factors have been identified for pathogenic periodontal bacteria. These 
virulence factors are related to surface components for attachment (pili, long fibers, capsules, 
vesicles), evasion of the host immune system (leukotoxin, chemtaxis inhibitors, lymphocyte 
alterations, immunoglobulin proteases, fibrinolysis, superoxide dismutase), enzymes 
(collagenase, acid phosphatase) and toxins (LPS).16 
More recently, the field of metagenomics has allowed the detailed description of bacterial 
community composition. Previously, such descriptions relied on culture methods, leaving a 
multitude of bacteria in biological samples unidentified. This is because the oral cavity harbors 
many fastidious bacteria that are difficult to isolate via culture methods. Now, with high- 
throughput sequencing techniques, such as 454 pyrosequencing, investigators are rapidly 
identifying new species associated with periodontal disease and health. Using 454 
pyrosequencing, for example, Griffen, et al. sequenced bacteria in subgingival plaque samples 
from 29 individuals who had periodontal disease and 29 individuals who were healthy.17 596 
7  
species were identified and unique, statistically significant differences in species prevalence were 
described between disease and healthy subjects. Interestingly, many of these species are 
uncultivable and are not described in the classic bacteria-complex model developed by 
Socransky6. 
Section 1.3 Periodontal disease and inflammation 
Inflammation is frequently viewed as a double-edged sword. On the one end, there is 
activation of the host’s immune system, the transition from innate to the adaptive immune 
response and the clearing of the immunologic challenge, such as bacteria or a foreign body. On 
the other end there is collateral damage that is often viewed as a negative consequence of the 
inflammatory process.  
However, one should consider that the destructive process serves as a protective function 
to the host. For example, in pregnant women, a septic infection in the mother triggers a large 
increase in TNF-a, which may stimulate the spontaneous delivery of the fetus to protect her from 
the infection in the mother. In periodontal disease, bacterial infections around teeth activate 
macrophages and fibroblasts to secrete inflammatory cytokines, which in-turn leads activation of 
osteoclasts and degradation of connective tissue and bone surrounding the teeth. 
As an end-result, this process places the host’s vital tissues, connective tissue and bone, 
at a greater distance from the bacteria and bacterial toxins, such as LPS and leukotoxins. This 
allows for epithelium down-growth and the creation of a wider buffer between noxious stimuli 
and the host’s vital tissues. In extreme cases, the entire tooth may exfoliate, which is again 
protective to the host, since now the portal for bacterial infection and progression has been 
eliminated. Nonetheless, the loss of connective tissue and bone from inflammation results in 
periodontitis. This process begins with gingivitis.  
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In the healthy periodontium, inflammatory cells, primarily neutrophils, are present in the 
gingival sulcus as a result of the presence of normal bacterial flora near the gingival sulcus. 
However, there is an equilibrium in existence here, whereby the amount and interactions of 
bacteria and inflammatory cells present do not lead to the irreversible destruction of the 
attachment apparatus of the tooth: connective tissue and bone. But, as the microbial challenge 
increases, there is increased collagen breakdown of the gingival tissues resulting from the 
stimulated release matrix metalloproteinases (MMPs) from macrophage and fibroblast cells. 
Clinically this manifests as edematous, red or cyanotic tissues that bleed easily on gentle 
pressure. This reversible, plaque-induced gingival lesion is known as gingivitis.  
Classic studies by Loe et al in the 1970s examined the natural progression of plaque 
induced gingival lesions in Sri Lankan tea laborers over a 15 year period18. It was the first study 
to assess tooth loss as a function of time using a group of tea laborers who performed no oral 
hygiene practices. The findings were that all individuals harbored large amounts of plaque and 
gingival inflammation around teeth. The progression of attachment loss around teeth and tooth 
mortality was assessed and 3 unique groups were identified based their rates of periodontal 
disease progression: rapid (8%), moderate (81%), and no progression (11%). Although most 
individuals lost periodontal attachment over time, some subjects never lost attachment despite 
large amounts of plaque and gingival inflammation. Thus the progression of periodontal disease 
is not the same for all individuals, nor is the loss of attachment a linear function.  
Prior to the 1980s, periodontal attachment loss was believed to be of a slow and 
continuous progression. However, many longitudinal human and animal studies have shown that 
some periodontal sites lose attachment at rates faster and slower than what would be expected 
from a continuous model process19,20. For example, radiographic analyses of periodontal bone 
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levels assessed longitudinally for 10 years revealed rates of bone loss inconsistent with a 
continuous model21. Socransky demonstrated in a cohort of 64 adults with no periodontal 
treatment over a 6 year period that individuals experienced an annual attachment loss of 0.18mm 
per site per subject; however, only 12% of all sites examined experienced attachment loss over 
2mm, which would be considered significant. Furthermore, of those sites experiencing >2mm of 
attachment loss in the first 3 years of the study, only 40% would progress further over the last 3 
years of the study22. Similar findings were also demonstrated in animal studies.23  
Socransky, et al studied and proposed a burst model for the rate of periodontal attachment 
loss22. He hypothesized that periodontal disease activity may be explained by a burst or 
asynchronous burst model, whereby individuals experience disease activity in random bursts 
with regard to time and history of previous attachment loss. Furthermore, these burst episodes 
may occur more frequently during certain periods of life, and subsequently become quiescent 
(asynchronous burst model). Although there is no proof that the burst hypothesis is true, it does 
help explain the shortcomings of the continuous model.  
In a review by Page, et al,24 the major “players” of the inflammatory-driven, periodontal 
destruction were identified and include the junctional epithelial cells, fibroblasts, leukocytes and 
cytokines- each player playing her part in the drama of inflammation. There seems to be 
equilibrium at play between inflammatory cytokines and anabolic growth factors, between 
periodontal destruction and periodontal repair and regeneration. Indeed, this is reflected in the 
classic study mentioned previously by Loe et al3. In that study, most individuals progressed to 
more severe forms of periodontitis; however, about 10% of individuals never progressed beyond 
gingivitis.  
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Therefore, balance between gingival inflammation and connective tissue destruction and 
extracellular matrix synthesis allowed for the disease to never progress beyond gingivitis. 
Animal and human studies on periodontitis have shown different time periods of disease activity 
balanced by disease quiescence and even repair19,20,22,23,25 . In fact, such is reflected in 
Socransky’s random burst models. Periodontal disease is not a linear, continuous function, but at 
certain points, anabolic growth factors and periodontal repair supersede cytokine-mediated 
destruction, which clinically is reflected in no further progression of attachment loss and in some 
instances, even attachment gain is detected. 
  Gingivitis can be divided into three separate stages: initial, early and established26. The 
initial lesion exhibits signs of acute inflammation with increased gingival fluid flow, enhanced 
neutrophil diapedesis, exudation and deposition of fibrin in the affected area. Collagen of the 
marginal gingiva may be destroyed in some areas. The early lesion exhibits an infiltrate of 
lymphocytes and macrophages with small amounts of plasma cells. Lymphocytes comprise the 
majority of cells, at roughly 75%. Vasculitis and large quantities of neutrophils in the junctional 
epithelium are observed. Resident fibroblasts undergo pathological changes and lymphocytes 
become activated. During the early phase, clinical signs of gingivitis may be present. The 
established phase consists histologically with large quantities of B-cells and plasma cells, in 
addition to T-cells. Large quantities of neutrophils in the sulcular epithelium are surrounded by 
macrophages in the lamina propria and lymphocytes in the connective tissue. Progression beyond 
the established lesion is the advanced lesion, which leads to periodontitis. Interestingly, in the 
established lesion there appears to be two types: those that remain stable and do not progress and 
those that progress and lead to periodontal destructive lesions.  
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There are 5 main innate protective mechanisms at play: neutrophils, epithelium, saliva, 
gingival crevicular fluid, high level of tissue turnover. Neutrophils are recruited from the 
systemic circulation into the gingival tissues, where they migrate towards the microbial plaque 
and chemo-attractants such as IL-8 secreted by epithelial cells. Over 500,000 neutrophils are 
estimated to migrate into the oral cavity per minute, in a normally functioning host27. Thus, the 
neutrophil serves as the first barrier to the underlying connective tissue and bone. Epithelial 
barriers include oral epithelium, oral sulcular epithelium, and junctional epithelium. The oral 
epithelium covers the underlying connective tissue and bone and is contiguous with the oral 
sulcular epithelium, which lines the sulcus, faces the tooth and continues to the junctinal 
epithelium. Junctinal epithelium separates the sulcus environment from the underlying 
connective tissue and bone. It is approximately 30 cell layers thick in its coronal aspect and 
tapers to approximately 3 cell layers in its most apical aspect28. Saliva has several important 
protective properties, including its flushing action, presence of secretory IgA, salivary 
agglutinins and presence of leukocytes. Gingival crevicular fluid is a serum transudate and 
contains many protective components including complement proteins, which are activated in 
inflammation and aid in phagocytosis. Lastly, high cell turnover rate is also protective, for as 
inflammatory-mediated host tissue destruction occurs, concurrently, anabolic host tissue 
synthesis occurs, creating an equilibrium that, in a healthy state, does not lead to attachment loss.   
The events that occur from established to advanced lesion include the microbial 
stimulation, via virulence factors such as LPS, of pro-inflammatory cells such as macrophages, 
to release of inflammatory cytokines IL-1, TNF-a, and PGE-2. T-lymphocytes also become 
activated and release IL-1 and lymphotoxin, which can stimulate macrophages and fibroblasts to 
produce matrix metallo-proteinases (MMP), which break down collagen in the extra-cellular 
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matrix29. Other cytokines help to regulate or reverse the response to the pro-inflammatory 
actions. For instance, transforming growth factor- b (TGF-b) suppresses production of MMPs, 
and IL-1 receptor antagonist competitively binds to IL-1 receptor but exhibits no pro-
inflammatory effect.  
 Section 1.4 Periodontal Disease in the setting of Immunesuppression 
It has been documented that individuals with HIV have a higher prevalence of 
periodontitis than individuals who are HIV negative, with some studies showing prevalence as 
high as 85%.30,31 Furthermore, HIV positive individuals may express unique forms of periodontal 
disease. Referred to as HIV associated periodontal disease, these conditions include linear 
gingival erythema (LGE), necrotizing ulcerative gingivitis (NUG), necrotizing ulcerative 
periodontitis (NUP) and necrotizing ulcerative stomatitis (NUS).32  
There is also a higher prevalence of oral fungal infections, including oral candidiasis, 
aspergillosis, cryptocossis, histoplasmosis, blastomycosis, paracoccidoidomycis, and 
zygomycosis33. Although with the availability of highly active anti-retroviral therapy (HAART) 
the prevalence of the HIV associated periodontal diseases has declined globally, they still remain 
a concern for patients and health care practitioners who treat these lesions when they occur.32  
In the context of immunosuppression, one must consider the importance of the potential 
for opportunistic infections to influence the severity of periodontal disease. Given the 
establishment of the important role of not only bacteria, but also viruses and fungi in periodontal 
disease, investigating the differences of the microbial flora between HIV positive and HIV 
negative individuals is important. In a comparison study of 8 periodontal putative pathogens in 
chronic periodontitis patients, significant differences in subgingival microbiota were detected 
between HIV positive and negative individuals.34 These same investigators also noted that the 
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periodontal pathogen, P.nigresens, was statistically associated with an increased odds for the 
presence of periodontal pathogens P. gingivalis, C. rectus, and T. denticola. In a Brazilian study 
performing a similar comparison, Goncalves, et al. reported that putative periodontal pathogens 
were found in greater numbers in HIV negative patients with chronic periodontitis than HIV 
positive patients. However, the HIV positive patients exhibited statistically significantly higher 
amounts of E. faecalis and A. baumannii, bacteria that are not usually associated with 
periodontal disease.35 Similar observations were made by other investigators.36,37 
 However, some studies have shown no difference between the subgingival microbiota of 
HIV positive and negative individuals. For example, Murray, et al. observed similar 
periodontopatogens in HIV positive chronic periodontitis individuals that is typically found in 
HIV negative chronic periodontitis patients. The investigator did find, however, that HIV 
associated gingivitis lesions consisted of a microbiota different from that commonly seen in HIV 
negative individuals38. Other studies have shown both the presence of typical periodontal 
pathogens along with atypical microorganisms that may play a role in the progression and 
severity of periodontal disease36,38–40 
Periodontal pathogens may also stimulate HIV reactivation in latently infected immune 
cells. Imai, et al. demonstrated in vitro that butyric acid-producing bacteria can increase HIV 
reactivation as detected by p24 antigen assay.41,42 Supernatant from periodontal pathogens F. 
nucleatum and P. gingivalis substantially induced HIV-1 replication, even beyond that of 
positive assay controls.  A different group, Huang, et al. demonstrated similar findings. Using 
HIV-infected T-cell, macrophage and dendritic cell lines, periodontal pathogens, including P. 
gingivalis, F. nucleatum, A. actinomycetemcomitans, C. rectus, and T. forsythia were shown to 
increase the promoter activation for HIV replication by as much as 34 fold in certain cell lines.43  
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Section 1.5 Viruses and Periodontal disease 
Clinical studies that have assessed the relationship between viruses and periodontal 
disease have consistently identified the human herpes viruses (HHV) in diseased samples. There 
are 8 HHVs known to man. Those that have been most commonly associated with periodontal 
disease include the Herpes Simplex Virus (HSV), Human Cytomegalo Virus (HCMV), and 
Epstein Barr Virus (EBV). Association studies have compared the prevalence of these HHVs 
between patients with periodontitis and gingivitis/shallow pocket sites.44–50  
When comparing HSV, EBV and HCMV detection in gingival biopsies of periodontally 
healthy vs. chronic periodontitis, Contreras et al. showed statistically significantly greater counts 
of HHVs in periodontal disease vs. health.44 Ting, et al. compared the prevalence of HHVs in 
deep vs. shallow sites of localized aggressive periodontitis patients and found that deeper, more 
diseased periodontal sites harbored a greater number of detectable HHVs than shallow, less 
diseased sites.51 In his review of viruses in periodontal disease, Cappuyns, et al. summarized the 
various association studies of Slots’ group and showed that in general, more diseased periodontal 
sites harbored a greater number of detectable HHVs than shallow, less diseased sites.52 
In a group of 10 subjects, Das, et al. collected subgingival plaque samples from patients 
with chronic and aggressive periodontitis and demonstrated a statistically significant associations 
between HSV-1 and EBV and periodontal disease.45 Whereas Das et al. utilized multiplex PCR 
for detection of virus, Kubar, et al. used real-time polymerase chain reaction (RT-PCR) to both 
detect and quantify HHVs in patients with chronic and aggressive periodontitis. Sites with the 
highest quantity of virus were detected which had the deepest probing depths.49 These studies are 
of great clinical relevance, as patients most afflicted by aggressive periodontitis tend to be 
adolescents and young adults and they experience a rapid loss of periodontal attachment, often in 
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the absence of plaque and calculus. Just as chronic periodontitis has been thought of as primarily 
a bacterial etiology without much consideration to viruses, so has the aggressive form of 
periodontitis. Increasing our knowledge and understanding of this relatively rare form of disease 
will enhance our abilities to treat it.  
The overall conclusion from these groups of studies is that HHVs are statistically 
associated with periodontal diseases, including gingivitis, localized and generalized chronic and 
aggressive periodontitis.  
Section 1.6 Potential mechanisms of viral and bacterial co-infections 
Recent studies have begun to elucidate molecular mechanisms by which bacteria could 
exacerbate viral pathogenesis in the oral cavity. The red complex bacterium Porphyromonas 
gingivalis and orange complex bacterium Fusobacterium nucleatum are widely studied in 
connection with periodontal disease and are Gram-negative, anaerobic, rod-shaped bacteria. P. 
gingivalis and F. nucleatum secrete a number of metabolic end products, including LPS, 
gingipains, outer membrane vehicles (OMVs), and short chain fatty acids (SCFAs) such as 
butyric acid53–58. Butyric acid levels can be up to 20 mM within the gingival pocket56,59,60. 
SCFAs like butyric acid are known histone deactylase inhibitors (HDACi)58 that may induce 
acetylation of histones within neighboring cells, leading to reactivation of latent viruses56,61–63. 
Molecular signaling pathways induced by SCFAs or other bacterial products may also contribute 
to epigenetic re-modeling or other mechanisms of viral induction. 
KSHV  
Kaposi’s Sarcoma Herpes Virus (KSHV) exhibits latent infection or active lytic infection, 
two distinct phases of replication, both of which are essential for long-term persistence of 
herpesviruses. Latent KSHV has been shown to be reactivated, or induced to enter the lytic phase 
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of replication, by spent media containing metabolic components from periodontal pathogens. In 
BCBL-1 cells with latent KSHV, reactivation has been observed following exposure to P. 
gingivalis or F. nucleatum spent media by a number of different assays, including transcription 
of the late lytic gene K8.1, production of RTA, v-Il6, and K8.1 proteins, Gardella gel showing 
production of linear viral genomes, presence of DNase-resistant DNA indicating virion 
production, and infectivity of these virions by observing production of LANA, RTA, and K8.1 in 
A293T cells infected the supernatant.62 Together, these assays demonstrate the full lytic cycle 
can be completed after exposure to P. gingivalis and F. nucleatum metabolic products. Further, 
only certain bacterial species have the ability to reactivate KSHV, with spent media from P. 
intermedia, S. aureus, and S. mutans failing to reactive KSHV.62  
Epigenetics play a critical role in regulation of KSHV gene expression64. Several studies 
have shown that a chemical agent, sodium butyrate (NaB), and other HDAC inhibitors increase 
acetylation of histones regulating of gene expression and lead to KSHV reactivation65–72. P. 
gingivalis and F. nucleatum spent media also have HDAC inhibition properties, as seen by a 
fluorimetric-based HDAC activity assay, that can increase global acetylation levels of H3 and 
H462. Following treatment with NaB or P. gingivalis or F. nucleatum spent media, increased 
histone acetylation was seen at the KSHV ORF50 as well as globally across the human 
genome62,73. In addition to inhibition of HDAC activity, SCFAs made by P. gingivalis and F. 
nucleatum decease expression of EZH2 and SUV39H1, two enzymes that repress transcription 
by mediating histone methylation, specifically H3K27me3 and H3K9me374. Bacterial spent 
media leads to increases in activating acetyl marks and decreases in repressive methyl marks, 
facilitating expression of KSHV.  
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Additional cellular pathways are modulated by P. gingivalis spent media and potentially 
involved in viral reactivation. Hypoxia, induced by increased reactive oxygen species, pro-
inflammatory cytokines, or by direct addition of hydrogen peroxide, is known to reactivate 
KSHV in BCBL-1 cells75,76. The hypoxia response has also been implicated in reactivation 
induced by P. gingivalis spent media by microarray studies in BCBL-1 cells showing marked 
induction of this pathway and confirmed by a hypoxia response element luciferase reporter 
assay. Further, a hypoxia-responsive kinase, PIM-1, showed increased protein levels in P. 
gingivalis spent medium treated cells. PIM-1 is required for KSHV reactivation by another 
chemical, TPA, and has been shown to phosphorylate KSHV LANA, the protein primarily 
responsible for maintaining latency. Phosphorylation of LANA by PIM-1 disrupts two functions 
of LANA, repression of transcription from the KSHV terminal repeat and repression RTA 
autoactivation, promoting viral reactivation77. There was no evidence of a hypoxia response to 
NaB treatment.  
In addition to the hypoxia response pathway, the p38 MAPK pathway is also involved in 
bacterium-mediated induction of the KSHV lytic cycle. The p38 inhibitors SB202190 and 
PD169316 significantly reduced P. gingivalis-mediated KSHV reactivation, including 
production of v-IL6 and K8.1 proteins62.  
EBV  
Spent media from P. gingivalis and F. nucleatum also induces lytic reactivation of 
another herpesvirus, EBV. In cells latently infected with EBV, P. gingivalis spent media induced 
expression of the BZLF1 gene product, ZEBRA, a transactivator for EBV lytic genes. This 
reactivation was least partially mediated by HDAC inhibition, attributed to butyric acid. 
Although P. gingivalis also produces isobutyric, propionic, acetic, and valeric acid, only butyric 
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acid treatment led to acetylation of H3, a mark of active chromatin, and induction of ZEBRA. 
ZEBRA expression also required structural remodeling of nucleosomal chromatin, as treatment 
with the topoisomerase II inhibitor novobiocin prevented P. gingivalis induced ZEBRA 
production63 78.  
HPV 
Unlike herpesviruses, HPV does not exhibit latent and lytic replication states. However, 
viral gene expression during the HPV lifecycle is tightly controlled and linked to epithelial 
differentiation79. High risk HPVs cause cervical, oropharyngeal, and other epithelial cancers, 
largely due to expression of the viral oncogenes E6 and E7, which repress p53 and Rb80,81. 
Recent studies have linked increased incidence of HPV+ oropharyngeal squamous cell 
carcinoma with chronic inflammation including periodontal disease82. Indeed, a recent study has 
observed increased gene expression of E6 and E7 and increased protein expression of E7 in 
HPV16+ SiHa cells in cells treated with P. gingivalis and F. nucleatum spent media for 6 or 24 
hrs. RNA-seq confirmed the increase in viral gene expression following exposure to bacterial 
spent media and dysregulation of cellular pathways involved in cancer pathogenesis and 
implicated in studies of bacterial-mediated modulation of other viruses, such as metabolism, 
invasion, the MAPK pathway, epigenetic regulation, and hypoxia response. P. gingivalis spent 
media induced reactive oxygen species production in SiHa cells and induced the hypoxia 
response, as confirmed by hypoxia response element luciferase reporter assay. In addition, the 
activating marks H3ac, H3K9ac, H3K27ac, and H3K36me3 were increased globally in SiHa and 
specifically on the HPV long control region following P. gingivalis spent media treatment. 
Increased HCK, ERK, and p38 phosphorylation were also observed, indicating dysregulation of 
cellular kinase pathways. Bacterial-mediated epigenetic changes and viral oncogene expression 
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were abrogated by SB202190 and PD169316 p38 inhibitors. Periodontal bacteria may contribute 
to oral carcinogenesis by promoting HPV oncogene expression by epigenetic remodeling, 
partially mediated by kinase signaling.   
Section 1.7 Summary 
The concepts of periodontal disease have evolved with the advent of better technologies 
to understand them. Since the Middle Ages, it has been understood that there was an association 
with poor oral hygiene, calculus and periodontal disease. In the 19th century the disease was 
conceptualized as autoimmune or degenerative, but in the 20th century that changed to one 
primarily involving bacteria and host response, and now the 21st century is recognizing the 
possible role of viruses in periodontal disease. 
There is ample evidence to support the role of bacteria as a causative agent for 
periodontal disease. Yet one must consider that the classical studies by Loe, Listgarten, Slots, 
Socransky, etc., often utilized culture and light microscopic methods to “see what’s there” in 
periodontally diseased sites. Today we know that there are a multitude of uncultivable bacteria in 
periodontal sites that may have a role just as significant as the red complex pathogens.  
Another uncultivable entity, outside of an infected host cell, is viruses. As obligate 
intracellular organisms, the only way to culture viruses are with living cells. The classical 
techniques used in the 70s and 80s would have missed the presence of viruses in periodontally 
diseased sites as growth media specific for bacteria was used. In the late 90s, researchers began 
investigating a possible association with herpes viruses and periodontal disease. The majority of 
these studies come primarily from one group of investigators, belonging to Slots’ group. This 
group was able to show statistically significant associations between various types of periodontal 
diseases and the presence of herpes viruses HSV, EBV and HCMV.  
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During immunosuppression, the nature of periodontal disease is different. Unique 
gingival lesions such as LGE, NUG, NUP and NUS may involve the presence of viruses, fungi 
and bacteria, and include many species not typically seen in an immunocompetent individual. 
Many studies have confirmed the presence of such atypical organisms in periodontally diseased 
sites,34–37 which may explain the reason that these individuals as a group have a higher 
prevalence of periodontitis.30,31  
Understanding that there is a significant association with herpes viruses and periodontal 
disease, and that there is also an undeniable role of bacteria in periodontal disease, one must 
consider if there is an interaction between viruses and bacteria during periodontal infection and 
whether this interaction can explain disease and disease progression. Studies have shown that 
bacterial metabolic end- products from periodonto-pathogenic organisms P. gingivalis (PG) and 
F. nucleatum (FN) may lead epigenetic modification of histones in herpes virus KSHV, which 
reactivates the virus to enter its lytic cycle of replication. Likewise, PG and FN have been shown 
in vitro to induce reactivation of EBV. Given the association between herpes viruses and the 
various forms periodontal disease, understanding the interaction between virus and bacteria is of 
great significance and needs further investigation. 
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CHAPTER 2: IMPACT OF PERIODONTAL INTERVENTION ON LOCAL 
INFLAMMATION, PERIODONTAL DISEASE AND HIV OUTCOMES 
 
Introduction  
Oral lesions associated with human immunodeficiency virus (HIV) include oral 
candidiasis, Kaposi’s sarcoma, lymphoma and hairy leukoplakia.83 During the era of 
antiretroviral therapy (ART), the prevalence of oral human papillomavirus (HPV) and HIV-
associated salivary gland disease has risen83,84. While HIV/AIDS-associated periodontal lesions 
including linear gingival erythema and necrotizing ulcerative periodontitis are not as prevalent as 
in the pre- ART era, chronic periodontitis remains an issue in the HIV/AIDS population84.  
Along with many other systemic diseases, HIV/AIDS has been documented to have 
impact on the periodontium32. Periodontitis is characterized by the host immune reaction to 
periodontal pathogenic microorganisms. While largely identified as an inflammatory disease 
caused by bacteria and bacterial by-products detected in dental plaque, there is growing evidence 
that viral infections are involved in periodontal disease.62,85 This inflammatory process is 
characterized by destruction of the attachment apparatus surrounding the teeth. The 2009–2012 
National Health and Nutrition Examination Survey (NHANES) estimates that 46% (64.7 million) 
of the US population has periodontitis, of which 8.9 and 37.1% suffer from severe and mild to 
moderate forms of the disease, respectively86. Increasing evidence suggests that the chronic 
periodontal infection is implicated in the generation of a systemic inflammatory response, which 
represents a potential risk factor for worsening various systemic conditions, including 
atherosclerosis, stroke, diabetes, and others87,88  
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Given its prevalence and impact, the detection and monitoring of periodontal disease 
progression is important. Chronic periodontal disease has been categorized using different 
classification systems. The most widely used classification system is based on clinical 
attachment levels, as described by Armitage and adopted by the American Academy of 
Periodontology (AAP)89. For the purposes of population surveillance, the Centers for Disease 
Control and Prevention developed a case classification in conjunction with the American 
Academy of Periodontology (CDC/AAP) based on periodontal probing depths and clinical 
attachment levels90. Lastly, the biofilm–gingival interface (BGI), a classification system based on 
bleeding on probing and probing depths, has been described91. The BGI classification reflects 
current periodontal status rather than historical levels of disease activity. Collectively, these 
systems may provide a better understanding of historic chronic disease, current status, and active 
disease and progression.  
The systemic impact of HIV is multifaceted. Broad depletion of immune function allows 
susceptibility to opportunistic infections92. Further, systemic immune activation occurs 
secondary to microbial translocation. The degree of immune activation is strongly correlated 
with disease progression, morbidity, and mortality93–97. Furthermore, decreased production of 
protective interleukins (IL), such as IL-6, IL-17, and IL-22, affects the epithelial tight junctions 
throughout the GI tract97 allowing for escape of immune-activating bacterial products into the 
systemic circulation. While immune activation-related microbial translocation from the gut has 
been well documented, the oral cavity may also serve as an important source of microbial 
translocation.  
The mouth may harbor over 700 different bacterial species, billions of bacteria, and a 
multitude of viruses and fungi. Teeth are transmucosal, with crowns exposed to the contaminated 
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oral cavity and root structures secured within maxillary and mandibular bone. The two 
environments are separated by a junctional epithelium that functions as a barrier to prevent the 
penetration of bacteria and bacterial products to underlying connective tissue and bone. During 
chronic periodontal disease, the junctional epithelia seal is widened, leading to the translocation 
of bacteria and bacteria by-products to the underlying connective tissue and bone28. Thus, 
chronic periodontal disease possesses the potential for oral microbial translocation as a source of 
systemic inflammation. This study aimed to determine the impact of periodontal treatment on 
local inflammation and systemic HIV status in a population of HIV-positive individuals.  
Section 2.1 Methods and Materials  
Setting  
This group was part of a prospective multicenter longitudinal study for Special Projects 
of the National Significance (SPNS) Oral Demonstration Project. 196 subjects were enrolled in 
the multicenter study. A cohort of 73 HIV- positive subjects recruited to the UNC site was 
identified for the present study and analysis. Approval was obtained from the Institutional 
Review Boards of the University of North Carolina at Chapel Hill (UNC) and the Evaluation 
Center for HIV and Oral Health at Boston University. Subjects were examined and treated at the 
UNC Hospital Dental Clinic. The multisite centers maintained human subjects’ approval for the 
overall and individual studies.  
Study design 
 At baseline, subjects received a comprehensive examination and treatment plan. Subjects 
were seen at least every 6 months for dental prophylaxis/ debridement, and information was 
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collected including periodontal metrics: probing depths, bleeding on probing, and clinical 
attachment level. Baseline, 12- and 24-month assessments were included in this analysis. At 
these time points, whole un-stimulated saliva was collected. Of the 73 study participants, only 45 
completed the study to the 24- month visit. Comprehensive dental care for the 73 participants 
included dental prophylaxis at least every 6months, scaling and root planing, oral hygiene 
instruction, extractions, restorative and prosthetic dental treatment.  
Additionally, a baseline interview was conducted that collected the following data: 
sociodemographic characteristics, mode of HIV transmission, past substance and tobacco, 
barriers to accessing oral health care since testing HIV positive, and oral healthcare habits. 
Interviews were conducted in both English and Spanish, and all participants gave informed 
consent to participate. Baseline data collection occurred from January 2008 to August 2011. 
Interviewers participated in a standardized training module. Interview and sample data were 
entered into a web-based database hosted by the multisite coordinating center, where the data 
were merged into a single multisite database. All examiners performing oral examinations and 
measures were calibrated to a gold standard with kappa score >0.9. CD4 counts and HIV viral 
load were recorded. Periodontal measures were also obtained and recorded. In a subset of 26 
subjects, saliva samples were collected for the measurement of pro-inflammatory cytokines.  
Participants  
Subjects who aged 18 and above, who were HIV positive, and who were out of dental 
care for at least 12 months were eligible. Subjects were referred from infectious disease 
specialists and community healthcare centers.  
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 Outcome variable   
The outcome of significance for the current analysis was periodontal status pre- and post-
intervention. Using the American Academy of Periodontology (AAP) and Centers for Disease 
Control and Prevention/AAP (CDC/AAP) and biofilm–gingival interface (BGI) classifications, 
participants were classified based on periodontal disease severity at baseline, 12 and 24 months. 
Changes in HIV viral load, CD4 and IL-6 levels and the relationships between demographics, 
HIV viral load, and concentration of IL-6 were also evaluated in the analyses.  
Predictor variable 
 Periodontal status at baseline, and the exposure is the periodontal intervention. Potential 
confounders and effect modifiers included antiretroviral therapy and time on antiviral therapy.  
Data sources  
Information for medical status including CD4 and HIV viral load (HIV VL) was 
abstracted from the patient’s medical chart. Periodontal disease classification was determined 
from the periodontal examination. Enzyme-linked immunosorbent assay (ELISA) was used to 
measure pro-inflammatory cytokine IL-6 levels (Quantikine Kit; R&D systems). Whole 
unstimulated saliva was collected and assayed in duplicate following the manufacturer’s 
instructions. Concentrations of the mediator were determined by optical density at the 
manufacturer’s recommended wavelength using a microplate reader (Epoch microplate 
spectrophotometer; Biotek). Duplicate readings were averaged, and the values were multiplied 
by the dilution factor.  
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Study size  
The study size was comprised of a convenience sample of 73 subjects. Table 2 displays 
the study schema. 
 
Section 2.2 Statistical analysis  
Statistical analysis was accomplished through SAS/STAT, version 9.3 (SAS Institute Inc. 
2011. STAT SAS 9.3 Procedures Guide, Cary, NC, USA: SAS Institute Inc.). Shifts in 
periodontal disease categories from baseline to 12 months were assessed separately by 
classification method using Bowker’s test of symmetry. For CD4, VL, and salivary IL-6, data 
were analyzed for subjects who were consecutively available for baseline and 12-, or baseline 
and 24-month appointments. Data points were non-parametrically distributed as determined by 
q-q plots. The changes in CD4, VL, and salivary IL-6 were com- pared across the 4 therapy 
groups none (not on ART at baseline), short (on ART for less than one year at baseline), long 
suppressed (on ART for >1 year at baseline with undetectable HIV viral loads), long not 
suppressed (on ART for >1 year at baseline with detectable HIV viral loads) using Kruskal–
Wallis analysis followed by Mann–Whitney pairwise comparisons between therapy groups. 
Wilcoxon matched pairs signed rank analysis was used to compare baseline and 12-month and 
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baseline and 24-month values for CD4, VL, and IL-6 separately for each therapy group. Binary 
logistic regression analysis was used to determine age-adjusted probabilities for moderate/severe 
periodontitis based on CDC/AAP classification using STATA statistical software. Level of 
significance was set at 0.05 for all analyses.  
Section 2.3 Results  
Participants  
A total of 73 subjects enrolled and were confirmed eligible in the UNC HIV 
Demonstration Project from 2008 to 2011; 73 were followed from baseline to 12 months, and 45 
participants were followed from baseline to 24 months. All underwent consecutive periodontal 
measurements every six months. There were 54 men and 19 women (Table 1). 
 
 
 
 
 
 
 
  Overall, the mean age of participants was 44; the majority of participants were non-
Hispanic (NH), Blacks (43), and Whites (24). For a full description of population demo- 
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graphics, see Table 1. Of individuals, 45% were smokers. At baseline, the overall mean CD4 and 
HIV viral load (VL) were 517 cells/ml and 72 043 copies/ml, respectively. At baseline, 
demographic values were collected and comprehensive oral examination with treatment planning 
was performed. Prophylaxis/debridement was carried out at baseline, 6, 12, 18, and 24 months 
(Table 2.) At baseline, 12 and 24 months, CD4 and HIV VL were obtained and whole un-
stimulated saliva was collected for the measurement of IL-6. For the 73 participants over the 
course of the study, there were 293 dental prophylaxis/periodontal maintenance procedures, 19 
scaling and root planing procedures, 33 periodontal debridements, 127 dental extractions, and 
325 dental restorations placed.  
 Dental intervention in HIV-positive subjects resulted in periodontal disease 
resolution Seventy-three HIV-positive subjects were classified according to AAP, CDC/AAP, 
and BGI periodontal disease classification systems (Table 3. and Figure 1).  
 
 
 
 
 
 
 
29  
AAP Classification- AAP measures periodontal disease based on clinical attachment 
levels, reflecting past disease status. The AAP classification at both baseline and post-
intervention categorized 87.6% of subjects as having mild periodontitis at both baseline and post-
intervention at 12 months. Pre- and post-intervention differences were not statistically significant 
for the AAP classification (P = 0.38, extended McNemar test). Of subjects, 4% improved by 1 
category and 6.8% decreased by 1 category. The perceived worsened disease status was likely 
due to gingival recession associated with disease resolution.  
AAP/CDC classification- AAP/CDC measures periodontal disease based on clinical 
attachment levels and probing depth based on a subset of sites, and this metric estimates disease. 
Using the AAP/CDC classification, 51% were classified in the moderate periodontitis group at 
baseline. At 12 months post-treatment, 13.7% of subjects improved by one category and 20.5% 
of subjects improved by 2 categories. The inclusion of periodontal pocket depths provides a 
measure of current disease status. However, pre- and post-intervention differences in 
classification were not statistically significant for the AAP/CDC classification (P = 0.255, 
extended McNemar test).  
BGI Classification- BGI measures periodontal disease based on bleeding on probing 
(BOP) values and probing depths, and this metric considers inflammation (BOP). The 
biologically based classification, BGI, determined that 63% of the subjects had severe disease at 
baseline. Post- treatment at 12 months, only 1 subject remained in the severe disease category, 
with increasing number of subjects categorized less severe categories. At 12 months post-
treatment, 56.2% of subjects improved by one category, 9.6% of subjects improved by two 
categories, and 9.6% of subjects improved by three categories. Thus, 54 patients showed 
improvement and pre- and post-intervention differences in classification were highly statistically 
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significant for the BGI classification (P < 0.0001, extended McNemar test). The improvement 
was likely due to the resolution of gingival inflammation. Compared to the AAP classification, 
the CDC/AAP and BGI classifications reflected current active disease and periodontal disease 
resolution over time (Figure 1).  
In HIV-infected subjects, differences in age, smoking, and income were not associated 
with more severe periodontal disease BGI case classifications were used to assess the frequency 
of periodontal health, gingivitis, and disease in the context of demographic variables. High 
prevalence of severe periodontal disease in the HIV cohort was detected across all income levels 
and across all ages (Figure 2). An equivalent number of smokers and non-smokers had severe 
periodontal disease. Severe periodontal disease was detected in 70% of HIV-positive NH Blacks 
and 50% NH Whites. At baseline, severe periodontal disease was detected in 63% of men and in 
63% of women with HIV infection. Similar percentages of men and women were detected in the 
moderate disease category.  
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Binary logistic regression analysis determined the likelihood of moderate/severe 
periodontal disease based on CDC/AAP classification (Figure 2). Moderate/severe periodontitis 
was positively associated with White and non-White races, smoking and non-smoking, male and 
female gender, all income levels, and all age groups. The probability of disease development was 
over 50% for both women and men and for both smokers and non-smokers. The probability of 
disease development was over 60% across all age groups and across all income levels. The 
probability of disease development was at least 50% for Whites and over 60% for Blacks and 
Hispanics.  
 ART and HIV status were associated with severe periodontal disease Of the 73 
individuals followed longitudinally for one year, at baseline 63 were on ART and 10 were not. 
Of those subjects on ART, 51 were on ART for at least 12 months at baseline. Of these 
individuals, 28 demonstrated undetectable viral load (Figure 3a). There were 45 individuals 
followed for 24 months, of whom 39 were on ART for at least 12 months at baseline. Of these 
individuals, 25 demonstrated viral suppression with undetectable viral load at baseline (Figure 
3b).  
 
 
 
 
  
33  
Regardless of ART status, over 80% of subjects had moderate/severe disease as determined by 
BGI classification (n = 73). BGI classification detected severe periodontal disease in 55% of 
those with undetectable viral loads (n = 28) and 75% of subjects on short-term ART (n = 12) 
Table 4. Interestingly, McNemar analysis did not detect statistically significant improvement in 
BGI classification using tests in the absence of ART (n = 10, P = 0.63), on short-term ART (n = 
12, P = 0.53), or on long-term ART who were not suppressed (n = 21, P = 0.09). This lack of 
statistical association may be related to the small size of the groups. However, in those on long-
term ART who were suppressed, a statistically significant improvement in BGI was detected (n = 
28, P = 0.026) Table 5b. At least fifty percent of subjects in each of the four groups demonstrated 
at least one category of periodontal improvement (Table 5a).  
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At baseline, the log median CD4 counts were similar across the groups ranged from 437 
to 469 cells/ml in those subjects who were on ART and 568 cells/ml in those who were not on 
ART. In the group of 45 participants at 24 months, all ART groups demonstrated statistically 
significant increases in CD4 count (n = 45, P = 0.007 to P = 0.01). At 24 months, median CD4 
counts in the group not on ART were 792 cells/ml, on short-term ART were 655 cells/ml, in the 
long-term ART-not-suppressed group were 783 cells/ml, and in the long-term ART-sup- pressed 
group were 647 cells/ml (Figure 4a). In those individuals on no ART, short-term ART, or on 
long-term ART who were not suppressed, differences in BGI were not significantly associated 
with changes in CD4 count at 24 months. However, in those who were in the long-term ART-
suppressed group, improved BGI/ periodontal status was associated with improved CD4 (P = 
0.0436). In the long-term ART-suppressed group, univariate analysis did not reach a statistical 
significance at 12 months (P = 0.058); however, by 24 months, a statistically significant 
association was detected between improved BGI and increased CD4 counts (P = 0.01). Of 
interest, in the group of subjects that were on long-term ART and not suppressed, univariate 
analysis detected highly statistically significant drops in viral load at both 12 months (P < 
0.0002) and 24 months (P = 0.0052) (Figure 4b). 
 Salivary pro-inflammatory cytokine levels were associated with an increased risk of 
developing moderate/severe periodontal disease The pro-inflammatory cytokine IL-6 was 
measured in the oral fluids from HIV-positive individuals (n = 26) (Figure 5). Age-adjusted 
predicted probabilities (95% CI) of moderate/severe periodontitis were determined. Those 
individuals with the highest IL-6 levels had a 60% probability of moderate/severe periodontal 
disease development at baseline (Figure 5a). Importantly, dental intervention resulted in overall 
decreased salivary IL-6 levels for all diseased groups, with the moderate group, P2, showing a 
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significant decrease from baseline to 24 months (P = 0.043) as determined by the Wilcoxon 
signed rank test (Figure 5b). At 12 months, IL-6 levels were assessed across ART groups. Mean 
IL-6 levels were highest at baseline in the long-term virologically suppressed group and 
demonstrated a significant decrease from baseline to 12 months (P = 0.031, Wilcoxon signed 
rank test) (Figure 5c).  
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Discussion  
Oral microbial load and associated inflammation may influence both local and systemic 
disease outcomes. In a group of HIV-positive subjects who were virologically suppressed at 
baseline, dental intervention was associated with decreased periodontitis, increased CD4 counts 
(P = 0.023) and decreased IL-6 (P = 0.03). While the data presented in this study do not remove 
the possibility that effective ART was responsible for viral load and CD4 count change in the 
other ART groups, it does suggest that decreased oral infection and inflammation were 
associated with improved HIV metrics.  
Inflammation is an important driver of both periodontal disease and HIV progression. 
Our observation of the utility of classification systems that include a measure of inflammation 
contributes to this literature. Increasing evidence suggests that the chronic periodontal infection 
is implicated in the generation of a systemic inflammatory response, which represents a potential 
risk factor for worsening systemic conditions87,88. Use of a periodontal classification system that 
reflects the biology of disease is an important metric in those with systemic inflammation- 
associated disorders. This was well illustrated in this study of HIV infected subjects with 
gingival inflammation. 
Of 73 individuals in our population, 63 were on ART and significant inflammation was 
detected that resolved with dental intervention and aggressive oral hygiene. Distinct profiles of 
periodontal disease and disease resolution were detected comparing different periodontal 
classification systems. While AAP provided an important glimpse of historical disease based on 
attachment levels, inclusion of probing depths in the CDC/AAP classification facilitated 
biological relevance. BGI included bleeding on probing as a metric, an important indicator of 
38  
oral and periodontal inflammation. With BGI, the majority of subjects were classified as severe 
at baseline. In previous studies, bleeding on probing was twice as high in an antiretroviral- 
untreated group compared to those on ART98. In our study regardless of ART status, 80% of 
subjects had moderate/severe disease at baseline using a classification system that includes 
current inflammation. Our findings were similar to the findings of John et al in a South African 
population where HIV stage and ART were not associated with higher levels of periodontal 
disease in HIV-positive subjects. In the South African group inclusion of a gingival index of 
inflammation reversed the significant association between antiretroviral therapy, probing depth 
and clinical attachment loss99. Of all classification systems, BGI, the inflammation-based 
classification system, demonstrated the most significant shifts in category associated with the 
dental intervention, moving virtually all individuals of the severe category into a moderate 
disease group by 12 months. These findings demonstrate the importance of including 
inflammation as a disease indicator. The periodontal field has now recognized the importance of 
this indicator, and a recent task force was convened to address the addition of bleeding on 
probing to the AAP classification to begin 2017100. 
In a Nationally representative sample, NHANES 2009- 2012, moderate/severe 
periodontitis was positively associated with non-white race, aging, smoking, male gender, and 
low income86. In our study of HIV positive individuals, frequency of periodontitis was high 
across all demographic variables, including gender, age and income. Interestingly, in our study 
there was not a significant difference with regard to smoking status. HIV may be a more 
important driver of the oral inflammatory process than the traditional demographic risk factors 
typically associated with periodontal disease in a nationally representative sample.  
Statistically significant decreases in HIV viral load were detected in the long-term ART 
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group who was not suppressed at baseline. The presence of detectable viral loads, however, may 
signify ineffective ART. Given that there were individuals with detectable viral load on ART, the 
improvement in HIV status could have been related to more effective ART use. At baseline, 50% 
of individuals on long-term ART in the severe disease group were undetectable, and by 24 
months, two-thirds of subjects in this group were undetectable. The dental intervention decreased 
oral microbial load and was associated with decreased low-level HIV viremia. Detectable HIV 
viral load has been associated with the presence of oral pathogens. A recent Brazilian study 
determined that detectable HIV VL was associated with elevated levels of known periodontal 
pathogens, such as P. nigrescens, T. forsythia, and E. corrodens101. There is also the potential for 
a direct pathogen–pathogen relationship, as others and we have shown that periodontal bacterial 
end products can increase HIV replication102. 
Periodontal disease is associated with circulating microbial products. Bacterial 
translocation into systemic circulation from the periodontal pocket is a common event, as 
supported by the detection of bacteremia subsequent to relatively minor periodontal events and 
procedures. The massive bacterial load of the gut is thought to drive microbial translocation, 
causing HIV-related systemic immune activation93. Importantly, oral antigens have been shown 
to facilitate trafficking of activated oral antigen-specific intestinal T-cell responses through 
CD18103. Hence, periodontal antigens may facilitate intestinal immune activation. We posit that 
the mouth contributes to microbial translocation in HIV- associated systemic immune activation. 
While periodontitis does not cause atherosclerotic vascular disease, periodontal interventions do 
result in reduced systemic inflammation104. Statistically significant improvement in BGI 
classification was detected in individuals who were virologically suppressed, suggesting 
improved local oral inflammation and supporting these previous results. Limitations were related 
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to the study size of this convenience population, particularly the small sample size of the 
virologically suppressed group. This does limit generalizability. However, this population and its 
distribution are similar to the demographic distribution of the HIV epidemic in the southeastern 
US. Despite the limitations, statistically significant changes were detected in the virologically 
suppressed group. Another limitation was retention rate at 24 months; baseline to 12 months 
there were 73 subjects followed longitudinally, at 24 months there were only 45 subjects seen at 
all 5 visits. Importantly, despite these limitations, in every group with detectable HIV VL at 
baseline, HIV VL was reduced with the intervention.  
It has previously been shown that the achievement of undetectable HIV VL was 
associated with decreased risk of comorbid events and strongly associated with increased CD4 
cells105. Low CD4 counts have previously been associated with chronic periodontitis in cross-
sectional studies106. In this study, a median sustained increase in CD4 count of over 100 cells/ml 
was detected with the dental intervention in a group of subjects who were suppressed at baseline. 
This suggests that over and above ART, dental interventions that diminish the oral microbial 
reservoir may provide a significant benefit to the immune system.  
Periodontal interventions in HIV significantly reduced periodontal inflammation that may 
be associated with systemic inflammation. Additional studies of systemic immune activation 
markers and periodontal disease resolution are needed. Here, we describe a simple and relatively 
inexpensive dental intervention that achieved decreased oral IL-6 and increased CD4 counts in a 
subset of individuals on effective ART.  
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CHAPTER 3: CONCLUSION  
 
From its early description in Ancient Egyptian times to the 21st century, our 
understanding of periodontal disease continues to evolve. Over the past 100 years, the 
periodontal literature has described the association with bacteria and periodontal disease. Since 
Van Leeuwenhoek’s description of microscopic organisms, bacteria have been isolated from 
periodontal pockets, visualized under the light microscope, and cultured. There is no denying the 
role of bacteria in periodontal disease. However, recent advances in molecular technology have 
revealed different players involved in this very complex disease, including uncultivable bacteria, 
viruses and inflammation. 
There is evidence that viruses are associated with periodontal disease. Numerous 
association studies have identified high prevalence of viruses in severe forms of periodontal 
disease and low levels in health and mild forms of disease. At the molecular level, bacterial by-
products, such as SCFAs and LPS, have been shown to lead to HHVs and HIV reactivation in 
latently infected immune cells. This process may result from microbial translocation and has 
significant impacts on individuals living with HIV. 
Over 20 million individuals are infected with HIV globally, with 1.2 million in the 
United States. Although many individuals are on HAART therapy, high amounts of systemic 
inflammation have been reported in the literature. Microbial translocation is particularly
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concerning in HIV positive individuals, as bacterial by-products have been shown to lead to 
reactivation of HIV in latently infected immune cells. The literature mostly describes the gut as 
the source of microbial translocation with little to no description of the mouth. The oral cavity is 
a highly contaminated environment; with of over 700 bacterial species and transmucosal teeth 
surrounded by billions of bacteria, the opportunity for microbial translocation is substantial, 
especially given the fact that nearly 50% of individuals have some form of periodontal disease. 
Thus, these bacterial by-products can easily pass through ulcerated gingiva and into the systemic 
circulation, and trigger immune reactivation of HIV. The contribution of periodontal disease to 
HIV immune status and vise versa is not well understood and has not been assessed in a 
longitudinal trial.  
There are distinct clinical and epidemiological differences in periodontal disease between 
HIV positive and HIV negative individuals. Those infected with HIV have a higher prevalence 
of periodontal disease and the demographic risk factors that are typically associated with an 
increased odds ratio for developing periodontitis do not show a clear relationship between their 
presence and increased odds for disease; instead, odds for moderate/severe periodontitis are 
high, regardless of demographics, indicating that having HIV overrides demographic variables.  
Determination of active periodontal disease status is important in HIV patients, as it has 
been demonstrated that inflammation is an important driver of HIV immune status. Thus 
classification systems that are more biologically based, such as BGI, should be considered above 
the more traditional classification systems, such as AAP, which classifies disease based on past 
history of periodontal destruction. Thus, BGI determines active disease and disease resolution 
whereas non-biologically based classification systems poorly discern between active and non-
active disease.  
43  
Reduction of oral microbial translocation and resolution of periodontal disease through 
treatment leads to significantly reduced inflammation, significantly increased CD4 counts, and 
significantly decreased VL counts. Thus relatively inexpensive and simple periodontal 
treatments, including oral hygiene instruction, scaling and root planning, periodontal 
debridement and maintenances may lead to profound, significant improvements in HIV immune 
status. 
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